Coherus BioSciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 306
- Market Cap
- $160.1M
- Website
- http://www.coherus.com
- Introduction
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered i...
Study of SRF617 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT04336098
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸City of Hope, Duarte, California, United States
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02650973
- Locations
- 🇺🇸
Medpace CPU, Cincinnati, Ohio, United States
🇺🇸WCCT, Cypress, California, United States
🇺🇸Spaulding, West Bend, Wisconsin, United States
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 545
- Registration Number
- NCT02489227
- Locations
- 🇵🇱
Centrum Badań Kliniccznych, Gdańsk, Poland
🇵🇱Niepubliczny Zaklad Opieki Zdrowtnej "NASZ LEKARZ", Toruń, Poland
🇿🇦Medicross Pretoria West 1st Floor, Pretoria West, Pretoria, South Africa
A Long Term Safety Extension Study (CHS-0214-05)
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 359
- Registration Number
- NCT02486939
- Locations
- 🇯🇵
Oribe Clinic of Rheumatism and Medicine, Oita, Ōita Prefecture, Japan
Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
- Conditions
- Interventions
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 303
- Registration Number
- NCT02418104
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸ICON, San Antonio, Texas, United States
🇺🇸Spaulding Clinical, West Bend, Wisconsin, United States
Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02385851
- Locations
- 🇺🇸
ICON, San Antonio, Texas, United States
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 521
- Registration Number
- NCT02134210
- Locations
- 🇺🇸
Radiant Research - Atlanta, Atlanta, Georgia, United States
🇺🇸Healthcare Partners Medical Group, Torrance, California, United States
🇺🇸Atlantic Clinical Research Collaborative, West Palm Beach, Florida, United States
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 647
- Registration Number
- NCT02115750
- Locations
- 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸Dream Team Clinical Research, Anaheim, California, United States
🇺🇸Arthritis Center of Nebraska, Lincoln, Nebraska, United States